OverviewSuggest Edit

Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt intends to develop Episalvan as a new treatment for a hereditary skin disorder called Epidermolysis Bullosa in both Europe and the U.S. Amryt’s earlier stage products are focused on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is high unmet medical needs. These include acromegaly and Cushing's disease.

HQGreater London, GB


Amryt Pharma is headquartered in
Greater London, United Kingdom

Location Map

Latest Updates

Employees (est.) (Jul 2016)4
Revenue (FY, 2018)£12.9 M(+14%)
Share Price (Oct 2020)£2
Cybersecurity ratingAMore

Key People/Management at Amryt Pharma

Joe Wiley

Joe Wiley

Chief Executive Officer, Director
Mark Sumeray

Mark Sumeray

Chief Medical Officer
David Allmond

David Allmond

Chief Commercial Officer
Stephen Joyce

Stephen Joyce

VP, Global Marketing
Kieran Rooney

Kieran Rooney

VP, Strategic Alliances and Licensing
Ray Stafford

Ray Stafford

Non-Executive Chairman
Show more

Amryt Pharma Office Locations

Amryt Pharma has offices in Greater London, London, Boston, Niefern-Öschelbronn and in 1 other location
Greater London, GB (HQ)
1 Adam St
London, GB
dept 920a, 196 High Rd, Wood Green
Niefern-Öschelbronn, DE
Streiflingsweg 11
Dublin, IE
90 Harcourt St, Saint Kevin's
Boston, US
160 Federal St floor 21
Boston, US
53 State St #500
Show all (6)

Amryt Pharma Financials and Metrics

Amryt Pharma Revenue

Embed Graph
View revenue for all periods
Amryt Pharma's revenue was reported to be £12.89 m in FY, 2018

Revenue (FY, 2018)


Gross profit (FY, 2018)


Gross profit margin (FY, 2018), %


Net income (FY, 2018)


EBIT (FY, 2018)


Market capitalization (16-Oct-2020)


Closing stock price (16-Oct-2020)


Cash (31-Dec-2018)



Amryt Pharma's current market capitalization is £317.5 m.
GBPFY, 2016FY, 2017FY, 2018



Cost of goods sold


Gross profit


Gross profit Margin, %

GBPFY, 2015FY, 2016FY, 2017FY, 2018



Accounts Receivable




Current Assets

GBPFY, 2015FY, 2016FY, 2017FY, 2018

Cash From Operating Activities


Cash From Investing Activities


Cash From Financing Activities


Net Change in Cash

GBPFY, 2015

Financial Leverage

1 x
Show all financial metrics

Amryt Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Amryt Pharma Online and Social Media Presence

Embed Graph

Amryt Pharma News and Updates

UK's Amryt Pharma unites lomitapide franchise with Aegerion deal

Britain's Amryt Pharma has agreed to buy Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, in a deal that reunites the franchise for lomitapide, a treatment for patients with a rare cholesterol disorder.

Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion

VANCOUVER, British Columbia and CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (Novelion), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that its wholly-owned subsid…

Amryt Pharma plc: Lojuxta to be reimbursed in France

17 October 2018 AIM: AMYT ESM: AYP

Amryt Pharma Frequently Asked Questions

  • When was Amryt Pharma founded?

    Amryt Pharma was founded in 2004.

  • Who are Amryt Pharma key executives?

    Amryt Pharma's key executives are Joe Wiley, Mark Sumeray and David Allmond.

  • How many employees does Amryt Pharma have?

    Amryt Pharma has 4 employees.

  • What is Amryt Pharma revenue?

    Latest Amryt Pharma annual revenue is £12.9 m.

  • What is Amryt Pharma revenue per employee?

    Latest Amryt Pharma revenue per employee is £3.2 m.

  • Who are Amryt Pharma competitors?

    Competitors of Amryt Pharma include GT Biopharma, Reata Pharmaceuticals and Flexion Therapeutics.

  • Where is Amryt Pharma headquarters?

    Amryt Pharma headquarters is located at 1 Adam St, Greater London.

  • Where are Amryt Pharma offices?

    Amryt Pharma has offices in Greater London, London, Boston, Niefern-Öschelbronn and in 1 other location.

  • How many offices does Amryt Pharma have?

    Amryt Pharma has 6 offices.